

patient reaction to the medication. We are therefore faced with the dilemma of a drug whose efficacy has been seriously questioned by excellent studies but which enjoys solid acceptance by the medical community and the patients it treats. At the present time, then, it would seem wise to consider Indocin as probably effective in rheumatoid arthritis pending further studies in this area. The drug is at the present time safe for use in this condition since in the dosages commonly employed there is very little risk of a serious adverse reaction. This author has recommended in the summary of the most recent supplement submitted by Merck, Sharp & Dohme that further studies be carried out to determine the efficacy of Indocin in rheumatoid arthritis.